PLEURAL MALIGNANT MESOTHELIOMA
Clinical trials for PLEURAL MALIGNANT MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new PLEURAL MALIGNANT MESOTHELIOMA trials appear
Sign up with your email to follow new studies for PLEURAL MALIGNANT MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug cocktail targets tough mesothelioma
Disease control OngoingThis study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) can help people with malignant pleural mesothelioma, a rare and aggressive cancer of the lung lining. About 117 participants who have not had prior treatment will receive either…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:43 UTC
-
New combo therapy targets tough mesothelioma
Disease control OngoingThis early-phase trial studies the safety of giving the immunotherapy drug pembrolizumab after radiation therapy for people with pleural mesothelioma, a rare and aggressive lung cancer. About 24 participants will receive the combination to see if it is tolerable and may help cont…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Targeted 'Trojan Horse' drug teams up with immunotherapy in fight against Asbestos-Linked cancer
Disease control OngoingThis study is testing whether adding a new targeted drug to an existing immunotherapy works better for treating a specific type of advanced lung cancer called pleural mesothelioma. The new drug acts like a guided missile, attaching to cancer cells and delivering a chemotherapy pa…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC